Calliditas IgAN Pocket Guide

IgA Nephropathy Pocket Guide

IgAN Pocket Guide Based on 2021 KDIGO Glomerular DIsease Guideline

Issue link: https://eguideline.guidelinecentral.com/i/1467690

Contents of this Issue

Navigation

Page 7 of 9

Agent Suggested Use Antiplatelet agents Not recommended Anticoagulants Not recommended Azathioprine Not recommended Cyclophosphamide Not recommended Calcineurin inhibitors Not recommended Rituximab Not recommended Fish oil Not recommended Mycophenolate mofetil (MMF) Chinese patients In those patients in whom glucocorticoids are being considered MMF may be used as a glucocorticoid-sparing agent. Non-Chinese patients There is insufficient evidence to support the use of MMF. Hydroxychloroquine Chinese patients In those patients who remain at high risk of progression in spite of optimized supportive care. Non-Chinese patients There is insufficient evidence to support the use in those patients. Figure 5. Practice Point 2.3.1.5: Other Pharmacologic Therapies Evaluated in IgAN Treatment

Articles in this issue

view archives of Calliditas IgAN Pocket Guide - IgA Nephropathy Pocket Guide